Nothing Special   »   [go: up one dir, main page]

MX2017004046A - Derivados de acido boronico. - Google Patents

Derivados de acido boronico.

Info

Publication number
MX2017004046A
MX2017004046A MX2017004046A MX2017004046A MX2017004046A MX 2017004046 A MX2017004046 A MX 2017004046A MX 2017004046 A MX2017004046 A MX 2017004046A MX 2017004046 A MX2017004046 A MX 2017004046A MX 2017004046 A MX2017004046 A MX 2017004046A
Authority
MX
Mexico
Prior art keywords
acid derivatives
boronic acid
abnomality
lmp7
inhibitors
Prior art date
Application number
MX2017004046A
Other languages
English (en)
Other versions
MX370336B (es
Inventor
Klein Markus
Schadt Oliver
Haselmayer Philipp
Busch Michael
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2017004046A publication Critical patent/MX2017004046A/es
Publication of MX370336B publication Critical patent/MX370336B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Los compuestos de la fórmula (I) son inhibidores de LMP7 y se pueden emplear, inter alia, para el tratamiento de una anormalidad de trastorno autoinmunitario o malignidades hematológicas. (ver Fórmula).
MX2017004046A 2014-10-01 2015-10-01 Derivados de acido boronico. MX370336B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14003392 2014-10-01
PCT/EP2015/002008 WO2016050359A1 (en) 2014-10-01 2015-10-01 Boronic acid derivatives

Publications (2)

Publication Number Publication Date
MX2017004046A true MX2017004046A (es) 2017-06-19
MX370336B MX370336B (es) 2019-12-10

Family

ID=51690789

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004046A MX370336B (es) 2014-10-01 2015-10-01 Derivados de acido boronico.

Country Status (14)

Country Link
US (1) US10294246B2 (es)
EP (1) EP3201207B1 (es)
JP (1) JP6835711B2 (es)
KR (1) KR102450583B1 (es)
CN (1) CN107001390B (es)
AU (1) AU2015327346B2 (es)
BR (1) BR112017006420A2 (es)
CA (1) CA2963205A1 (es)
ES (1) ES2873000T3 (es)
IL (1) IL251301B (es)
MX (1) MX370336B (es)
RU (1) RU2017115188A (es)
SG (1) SG11201702623TA (es)
WO (1) WO2016050359A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017004043A (es) 2014-10-01 2017-07-04 Merck Patent Gmbh Derivados de acido boronico.
JP6835710B2 (ja) 2014-10-01 2021-02-24 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung ボロン酸誘導体
MX2017003999A (es) 2014-10-01 2018-02-09 Merck Patent Gmbh Derivados de acido boronico.
KR20200040295A (ko) * 2017-08-24 2020-04-17 메르크 파텐트 게엠베하 보론산 유도체
IL280376B2 (en) * 2018-07-26 2024-08-01 Merck Patent Gmbh The history of boronic acid, its preparation and pharmaceutical preparations containing it
CN113135944A (zh) * 2020-01-19 2021-07-20 首药控股(北京)有限公司 硼酸衍生物
CN113135943A (zh) * 2020-01-19 2021-07-20 首药控股(北京)有限公司 硼酸衍生物
EP4301466A1 (en) * 2021-03-02 2024-01-10 Case Western Reserve University B-lactamase inhibitors and uses thereof
US20240287102A1 (en) 2021-07-29 2024-08-29 Merck Patent Gmbh Novel crystalline forms of [(1r)-2-(1-benzofuran-3-yl)-1-{[(1s,2r,4r)-7-oxabicyclo[2.2.1]heptan-2-yl]formamido}ethyl]boronic acid, adducts thereof, and processes to obtain
CN118119630A (zh) * 2021-10-14 2024-05-31 首药控股(北京)股份有限公司 硼酸衍生物
WO2023232830A1 (en) 2022-06-02 2023-12-07 Merck Patent Gmbh Boronic acid adducts

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111175A0 (en) * 1993-10-07 1994-12-29 Du Pont Merck Pharma Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them
AU5788800A (en) * 1999-07-07 2001-01-22 Du Pont Pharmaceuticals Company Peptide boronic acid inhibitors of hepatitis c virus protease
US7271186B1 (en) 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
EP2220097A1 (en) * 2007-11-13 2010-08-25 Protez Pharmaceuticals, Inc. Beta-lactamase inhibitors
AR075090A1 (es) * 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
AU2012356890B2 (en) * 2011-12-22 2017-06-08 Ares Trading S.A. Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors
MX2017004043A (es) 2014-10-01 2017-07-04 Merck Patent Gmbh Derivados de acido boronico.
JP6835710B2 (ja) 2014-10-01 2021-02-24 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung ボロン酸誘導体
MX2017003999A (es) 2014-10-01 2018-02-09 Merck Patent Gmbh Derivados de acido boronico.

Also Published As

Publication number Publication date
JP2017536335A (ja) 2017-12-07
EP3201207B1 (en) 2021-02-24
MX370336B (es) 2019-12-10
KR102450583B1 (ko) 2022-10-04
JP6835711B2 (ja) 2021-02-24
ES2873000T3 (es) 2021-11-03
WO2016050359A1 (en) 2016-04-07
AU2015327346A1 (en) 2017-05-18
CN107001390B (zh) 2020-11-27
US10294246B2 (en) 2019-05-21
KR20170062517A (ko) 2017-06-07
CN107001390A (zh) 2017-08-01
US20180105539A1 (en) 2018-04-19
IL251301A0 (en) 2017-05-29
AU2015327346B2 (en) 2019-12-05
SG11201702623TA (en) 2017-04-27
BR112017006420A2 (pt) 2017-12-19
RU2017115188A3 (es) 2019-03-29
CA2963205A1 (en) 2016-04-07
EP3201207A1 (en) 2017-08-09
IL251301B (en) 2022-02-01
RU2017115188A (ru) 2018-11-06

Similar Documents

Publication Publication Date Title
PH12017500293A1 (en) Boronic acid derivatives
MX2017004037A (es) Derivados de acido boronico.
MX2017004043A (es) Derivados de acido boronico.
MX2017004046A (es) Derivados de acido boronico.
IL259787A (en) Mutant isocitrate dehydrogenase 1 (idh1) suppressor for the treatment of malignancies
PH12017500509A1 (en) Benzyl substituted indazoles as bub1 inhibitors
NZ735998A (en) Heterocyclic compounds as lsd1 inhibitors
NZ724691A (en) Quinoline derivatives as smo inhibitors
MX2016012829A (es) Inhibidores de biaril cinasa.
TW201613886A (en) 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
PH12017500745A1 (en) Bromodomain inhibitors
AU2015299431B2 (en) Pyrrolidinone derivatives as metAP-2 inhibitors
MX2016002924A (es) Inhibidores de cinasa a base de eter arilico.
MX2015009818A (es) Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerosis multiple.
PH12017501071A1 (en) Dihydropyrimidin-2-one compounds and medical use thereof
MA39824A (fr) Composés azole amido-substitués
MX2016009355A (es) Inhibidores de aril lactama cinasa.
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
EA201791099A1 (ru) Хинолин карбоксамиды для применения в лечении лейкоза
PH12016501183A1 (en) Novel compound for treatment of severe hypoglycemia
PH12016501184A1 (en) Novel compound for treatment of severe hypoglycemia
TN2016000181A1 (en) Novel compound for treatment of severe hypoglycemia.
TW201613928A (en) Vinyl compounds as inhibitors for FGFR and VEGFR
UA95450U (uk) 2-(6-етокси-2-метилхінолін-4-ілтіо)-сукцинатна кислота, що проявляє антиоксидантну активність

Legal Events

Date Code Title Description
FG Grant or registration